Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial

N Duffy, P Walker, F Diamantea, P M A Calverley, L Davies

Background: Intravenous aminophylline is commonly used in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD), despite limited evidence for its efficacy and known risks of toxicity. We hypothesised that adding intravenous aminophylline to conventional treatment would not produce clinically important changes in the speed of spirometric or symptomatic recovery or shorten hospital stay in patients with exacerbations of COPD.

Methods: Eighty patients admitted to hospital with non-acidotic exacerbations of COPD were recruited at admission to a randomised, double blind, placebo controlled study comparing intravenous aminophylline 0.5 mg/kg/hour after an appropriate loading dose with an equivalent volume of 0.9% saline. The primary outcome was the change in post-bronchodilator forced expiratory volume in 1 second (FEV₁) over the first 5 days of the admission. Secondary end points were changes in self-reported breathlessness, arterial blood gas tensions, forced vital capacity (FVC), and length of hospital stay.

Results: There was no difference in the post-bronchodilator FEV₁ over the first 5 days between the aminophylline and placebo groups. In the aminophylline group, 2 hours of treatment produced a small but significant rise in arterial pH (p = 0.001) and a fall in arterial carbon dioxide tension (p = 0.01) compared with placebo treatment. There were no differences in the severity of breathlessness, post-bronchodilator FVC, or length of hospital stay between the groups. Nausea was a more frequent side effect in the aminophylline group (46% v 22%; p < 0.05), but palpitations and headache were noted equally in both groups.

Conclusions: Although intravenous aminophylline produced small improvements in acid-base balance, these did not influence the subsequent clinical course. No evidence was found for any clinically important additional effect of aminophylline treatment when used with high dose nebulised bronchodilators and oral corticosteroids. Given its known toxicity, we cannot therefore recommend the use of intravenous aminophylline in the treatment of non-acidotic COPD exacerbations.

HOSPITALISATION DUE TO AN EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Given the limited data available, we hypothesised that intravenous aminophylline would not change post-bronchodilator lung function or the rate of symptom recovery in patients admitted to hospital with COPD exacerbations, and would not reduce the time to discharge or the subsequent relapse rate. To test these hypotheses we conducted a prospective, double blind, randomised, parallel group trial comparing intravenous aminophylline and placebo given from the time of hospital presentation and followed throughout the admission and, where possible, until 6 weeks after discharge.

METHODS

Patients

Patients with a clinical diagnosis of COPD presenting to the emergency department of University Hospital Aintree were considered eligible if they complained of increased breathlessness and two or more of the following symptoms for at least 24 hours: increased cough frequency or severity, increased sputum volume or purulence, increased wheeze. Patients were aged 40–80 years with a smoking history of at least 20 pack years, an initial forced expiratory volume in one second (FEV₁) of less than 60% of predicted, and a forced expiratory volume in 1 second (FEV₁) to forced vital capacity (FVC) ratio less than 0.7. Patients were excluded if they had a history of congestive heart failure, recent myocardial infarction, or angina, or if they were taking theophylline, theophylline derivatives, or oral aminophylline at the time of admission.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity

Dr L Davies, Aintree Chest Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK; lisa.davies@ahl.nwest.nhs.uk

Correspondence to:

October 2004

Published Online First

6 June 2003

See end of article for authors’ affiliations

Accepted 30 May 2005

Published Online First

6 June 2003
capacity (FVC) ratio of <70% predicted, and FEV₁/forced vital
uncontrolled cardiac disease, advanced malignancy, clinical or
control of eosinophil count. An arterial blood sample was
taken, with patients breathing room air whenever possible,
for blood gas analysis; this was repeated after 2 hours of
treatment. The serum theophylline level was measured if the
patient was receiving an oral theophylline preparation
(Olympus turbidometric assay; lower limit <5 μmol/l, the
curve is linear to 160 μmol/l; normal range 55–110 μmol/l).
Sputum was collected, if produced, for microscopy, culture,
and sensitivity. A breathlessness severity score at the time of
admission was recorded using both the modified Borg
category scale and a 100 mm visual analogue scale on which
patients were asked to score their condition between 0 (no
shortness of breath) and 100 (shortness of breath as bad as
can be). Post-bronchodilator spirometric parameters were
recorded using a dry bellows spirometer (Vitalograph Model
2150, Buckingham, UK) to American Thoracic Society standards.13 At least three forced expiratory manoeuvres
were obtained on each occasion until two were within 5%.
Data are expressed relative to the European Steel and Coal
standards.13

Study design
One investigator (ND) took a detailed medical history and
examined patients within 4 hours of hospitalisation. On
admission, blood was taken for a full blood count, including
absolute eosinophil count. An arterial blood sample was taken,
with patients breathing room air whenever possible,
for blood gas analysis; this was repeated after 2 hours of
treatment. The serum theophylline level was measured if the
patient was receiving an oral theophylline preparation
(Olympus turbidometric assay; lower limit <5 μmol/l, the
curve is linear to 160 μmol/l; normal range 55–110 μmol/l).
Sputum was collected, if produced, for microscopy, culture,
and sensitivity. A breathlessness severity score at the time of
admission was recorded using both the modified Borg
category scale and a 100 mm visual analogue scale on which
patients were asked to score their condition between 0 (no
shortness of breath) and 100 (shortness of breath as bad as
can be). Post-bronchodilator spirometric parameters were
recorded using a dry bellows spirometer (Vitalograph Model
2150, Buckingham, UK) to American Thoracic Society standards.13 At least three forced expiratory manoeuvres
were obtained on each occasion until two were within 5%.
Data are expressed relative to the European Steel and Coal
Company predicted values. All patients were treated with
both a nebulised β agonist (salbutamol 5 mg) and an
anticholinergic (ipratropium 500 μg) every 6 hours, con-
trolled oxygen therapy, intravenous or oral antibiotics at
the physician’s discretion, and oral prednisolone 30 mg daily
for 14 days.

Patients were randomly assigned to treatment with
intravenous aminophylline or saline; the study drug (which
was identically packaged) was diluted in saline to a
concentration of 1 mg/ml and a loading dose of 5 mg/kg
body weight was given over 30 minutes. Subsequently,
infusion at a rate of 0.5 mg/kg body weight/hour was
continued until the physician in charge of the patient (who
was not a study investigator) felt it appropriate to discon-
tinue treatment because of clinical improvement or adverse
effect. The placebo was given in the same manner so that a
similar volume of fluid was infused. If the patient was taking
an oral theophylline preparation before admission, the
loading dose was omitted and the oral preparation was
discontinued. Randomisation was performed using a com-
puter generated random number table. Packages of treatment
were numbered in advance and used sequentially.

Blood was taken on day 1 of the study for measurement of
serum theophylline levels. The result was sent to another
team member (not an investigator) who issued dummy
results where appropriate to maintain the blinding. The rate of
infusion was adjusted as appropriate and serum theophyl-
line levels were rechecked as needed. All patients, inves-
tigators, and other hospital staff were masked to treatment status
throughout the study.

Further assessments were carried out at 12 hours and then
daily for 5 days (unless discharged from hospital before this
time) and again on the day the patient was thought fit for
discharge. At each assessment, made 30 minutes after the
bronchodilator was given, spirometric tests were repeated; a
daily symptom score was recorded by assessing whether patients felt the same, better, or worse overall compared with
the previous day; and a Borg score for breathlessness,
measurements of respiratory rate, and percentage oxygen
saturation were recorded. In addition, we asked about possible side effects of aminophylline (headache, nausea,
and palpitations).

Patients could be withdrawn at any time if they or their
physician (not an investigator) felt clinical improvement was
unsatisfactory, and patients were automatically withdrawn if
the arterial pH fell below 7.32. The patients’ physicians
decided when they were medically fit for discharge, and this
date was used in the study analysis. At discharge, spirometric
tests and the visual analogue breathlessness score were
repeated, a St George’s Respiratory Questionnaire was
completed to assess the patients’ health status,14 and an
assessment was made by the investigator as to whether the
study treatment had been helpful.

Patients were reviewed 6 weeks after discharge with
repeat spirometric testing after 5 mg nebulised salbutamol
and the St George’s Respiratory Questionnaire. Data were
collected about any treatment changes since discharge and
whether there had been any further exacerbations. The
6 week visit was postponed if the patient had had a further
exacerbation. Patients not returning were contacted by
telephone and their vital status and exacerbation history
confirmed.

The study funders had no part in the design, the running of
the study, or the data analysis.

Statistical analysis
The primary end point was the change in post-bronchodilator
FEV₁ over the first 5 days following admission; secondary

<table>
<thead>
<tr>
<th>320 screened</th>
<th>188 not eligible</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not COPD</td>
<td>35</td>
</tr>
<tr>
<td>pH&lt;7.30</td>
<td>25</td>
</tr>
<tr>
<td>Not COPD exacerbation</td>
<td>23</td>
</tr>
<tr>
<td>Already on aminophylline</td>
<td>23</td>
</tr>
<tr>
<td>Assisted discharge</td>
<td>20</td>
</tr>
<tr>
<td>Consolidation on CXR</td>
<td>15</td>
</tr>
<tr>
<td>No smoking history</td>
<td>10</td>
</tr>
<tr>
<td>Previous thoracic surgery</td>
<td>9</td>
</tr>
<tr>
<td>Confused</td>
<td>7</td>
</tr>
<tr>
<td>Others</td>
<td>21</td>
</tr>
</tbody>
</table>

Figure 1 CONSORT diagram indicating progress of patients through the clinical trial.
end points were changes in breathlessness as measured by the Borg and visual analogue scales, changes in arterial blood gases from baseline to 2 hours after treatment, changes in FVC, and length of hospital stay.

Given the hazards of theophylline treatment, we decided that it could only be justified if it was accompanied by a clinically important improvement in FEV1, equivalent to an improvement of 300 ml within the study period. We calculated that a sample size of 37 in each group would give 80% power to detect a difference of 200 ml in FEV1 between aminophylline and placebo, assuming that the common standard deviation is 300 ml using a two group t test with a 5% two sided significance level. Hence, we aimed to recruit 40 patients per group. All data were analysed using SPSS Version 11. Student’s t tests, ANCOVA, and ANOVA were used to compare normally distributed data. Data are expressed as mean and 95% confidence intervals (CI). The assumptions of the model were checked by inspection of the residuals.

RESULTS

Of 320 patients screened for the study, 132 met the inclusion criteria (fig 1). The most common reason for exclusion was breathlessness for reasons other than COPD. Thirty nine criteria (fig 1). The most common reason for exclusion was breathlessness for reasons other than COPD. Thirty nine patients received active treatment and 41 placebo. Of the 65

---

**Table 1**: Baseline characteristics of the two groups on admission

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 41)</th>
<th>Aminophylline (n = 39)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>67.4 (65.1 to 69.7)</td>
<td>69.6 (67.1 to 72.1)</td>
<td>0.22</td>
</tr>
<tr>
<td>M/F</td>
<td>22/19</td>
<td>13/26</td>
<td>0.07</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.9 (21.0 to 24.8)</td>
<td>24.1 (22.0 to 26.2)</td>
<td>0.41</td>
</tr>
<tr>
<td>Smoking (pack years)</td>
<td>57.1 (47.5 to 66.7)</td>
<td>46.2 (35.2 to 55.2)</td>
<td>0.11</td>
</tr>
<tr>
<td>Duration of symptoms</td>
<td>10.7 (8.4 to 12.0)</td>
<td>9.2 (6.8 to 11.6)</td>
<td>0.38</td>
</tr>
<tr>
<td>Years of COPD</td>
<td>12.0 (8.1 to 15.9)</td>
<td>9.3 (6.9 to 11.7)</td>
<td>0.24</td>
</tr>
<tr>
<td>VAS score</td>
<td>74.7 (68.8 to 81.0)</td>
<td>66.4 (59.7 to 73.1)</td>
<td>0.08</td>
</tr>
<tr>
<td>Borg score</td>
<td>5.0 (4.4 to 5.6)</td>
<td>5.1 (4.4 to 5.8)</td>
<td>0.77</td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>0.64 (0.54 to 0.74)</td>
<td>0.65 (0.57 to 0.73)</td>
<td>0.84</td>
</tr>
<tr>
<td>FVC (l)</td>
<td>1.76 (1.58 to 1.94)</td>
<td>1.65 (1.47 to 1.83)</td>
<td>0.40</td>
</tr>
<tr>
<td>Eosinophil count (%)</td>
<td>1.9 (1.3 to 2.5)</td>
<td>1.4 (0.7 to 2.1)</td>
<td>0.30</td>
</tr>
<tr>
<td>No (%) on oral theophylline</td>
<td>12 (29%)</td>
<td>8 (21%)</td>
<td>0.25</td>
</tr>
<tr>
<td>Theophylline level (µmol/l)</td>
<td>61 (47 to 75)</td>
<td>88 (72 to 104)</td>
<td>0.58</td>
</tr>
<tr>
<td>pH</td>
<td>7.41 (7.40 to 7.42)</td>
<td>7.42 (7.40 to 7.44)</td>
<td>0.26</td>
</tr>
<tr>
<td>PaO₂</td>
<td>7.46 (6.99 to 7.94)</td>
<td>7.67 (7.21 to 8.13)</td>
<td>0.51</td>
</tr>
<tr>
<td>PaCO₂</td>
<td>5.96 (5.57 to 6.35)</td>
<td>5.46 (5.04 to 5.87)</td>
<td>0.07</td>
</tr>
</tbody>
</table>

Values are mean (95% CI) or numbers (%).

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PaO₂, PaCO₂, arterial oxygen and carbon dioxide tension.

The mean number of days the study drug was given was 1.7 (95% CI 1.3 to 2.1) in the aminophylline group and 2.3 (95% CI 1.0 to 2.0) in the placebo group (p = 0.058). The mean theophylline level on the day following admission in the aminophylline group was 73.4 µmol/l (95% CI 62.9 to 83.9) while in the placebo group it was 2.5 µmol/l (95% CI 0.5 to 4.5); in the 11 subjects receiving placebo who used oral theophylline the mean level was 9.0 µmol/l (95% CI 3.3 to 14.7).

From admission to discharge the FEV1 increased more with placebo than with aminophylline treatment (p = 0.048). When analysed over the first 5 days after admission with FEV1 or FVC on admission (as appropriate) as a covariate, there was no significant difference in the change in FEV1 or FVC between the two groups (p = 0.49); this was also true for...
the first 24 hours \( (p = 0.46) \) when all but two subjects (both in the aminophylline group) remained on study medication (fig 2). Prior use of theophylline did not affect these results.

Arterial blood gas data were available in all subjects on admission and 2 hours later. In 70 patients both the admission and 2 hour samples were taken breathing room air (table 2). There was a significant difference in the change in arterial pH and PaCO₂ over the first 2 hours of treatment between the groups, with the aminophylline group showing a larger increase in pH \( (p = 0.001) \) and a larger fall in PaCO₂ \( (p = 0.01) \) which was not influenced by prior theophylline use. The change in respiratory rate did not differ from admission to discharge between groups (from 23.9 \( (95\% \text{ CI} 22.0 \text{ to } 25.8) \) to 22.2 \( (95\% \text{ CI} 22.0 \text{ to } 25.0) \) in the aminophylline group), nor was there a difference in the change in symptom score (table 3). Blinded evaluation of treatment efficacy could not distinguish between placebo \( (\text{helpful in } 42\%) \) and the active drug \( (\text{helpful in } 49\% \); \( p = 0.56) \).

The mean length of hospital stay analysed on an intention to treat basis for all 78 patients who survived was 7.7 days \( (95\% \text{ CI } 6.8 \text{ to } 8.6) \). In the aminophylline group the mean length of stay in hospital was 7.1 days \( (95\% \text{ CI } 5.9 \text{ to } 8.3) \) compared with 8.2 days \( (95\% \text{ CI } 7.0 \text{ to } 9.4) \) for the placebo group \( (p = 0.19, \text{fig 3}) \).

More patients in the aminophylline group complained of nausea than in the placebo group \( (46\% \text{ v } 22\%; \chi^2 <0.05) \). In the aminophylline group 10 patients complained of palpitations and 14 of headache compared with seven and 13 patients respectively in the placebo group \( (p = 0.56) \).

DISCUSSION

This is the first adequately powered trial to study whether adding intravenous aminophylline to conventional treatment benefits patients with COPD exacerbations, either acutely or following discharge from hospital. We found no evidence of any clinical or physiological benefit during the hospital stay, nor did the use of intravenous aminophylline shorten hospitalisation significantly or influence subsequent progress. Our patient groups were well matched at admission. All received identical medical treatment and trial treatment was blinded to the investigator by the use of dummy theophylline levels in those receiving placebo. The magnitude of change in lung function was similar to that reported previously by us during the recovery from an exacerbation. The lack of any statistical or clinically significant difference in FEV₁ between treatment arms, either early or late in the course of the illness, is in keeping with the data from Rice et al who studied similar patients, and it suggests that aminophylline is not providing additional bronchodilatation beyond that achieved with high dose nebulised treatments. Although it

---

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Aminophylline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admission (n = 36)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.41 (7.40 to 7.42)</td>
<td>7.42 (7.40 to 7.44)</td>
</tr>
<tr>
<td>PaO₂ (kPa)</td>
<td>7.46 (6.98 to 7.94)</td>
<td>7.6 (7.21 to 8.13)</td>
</tr>
<tr>
<td>PaCO₂ (kPa)</td>
<td>5.96 (5.57 to 6.35)</td>
<td>5.46 (5.04 to 5.87)</td>
</tr>
<tr>
<td>2 hours (n = 34)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.41 (7.40 to 7.42)</td>
<td>7.44 (7.43 to 7.45)</td>
</tr>
<tr>
<td>PaO₂ (kPa)</td>
<td>7.54 (7.11 to 7.97)</td>
<td>7.77 (7.30 to 8.24)</td>
</tr>
<tr>
<td>PaCO₂ (kPa)</td>
<td>5.79 (5.42 to 6.16)</td>
<td>4.99 (4.62 to 5.36)</td>
</tr>
</tbody>
</table>

Values are means \( (95\% \text{ CI}) \).

---

### Table 3

<table>
<thead>
<tr>
<th></th>
<th>Aminophylline</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fall in Borg score from admission to discharge</td>
<td>2.6 (1.7 to 3.5)</td>
<td>2.4 (1.6 to 3.2)</td>
</tr>
<tr>
<td>Fall in VAS score from admission to discharge</td>
<td>26 (16.1 to 35.9)</td>
<td>36.8 (27.5 to 36.1)</td>
</tr>
<tr>
<td>Self-reported symptomatic improvement over first 24 hours of admission</td>
<td>48.6%</td>
<td>58.5%</td>
</tr>
<tr>
<td>Self-reported symptomatic improvement from admission to day 5</td>
<td>87.2%</td>
<td>85.4%</td>
</tr>
<tr>
<td>Physician reported improvement with study drug from admission to discharge</td>
<td>48.1%</td>
<td>42.1%</td>
</tr>
</tbody>
</table>

There were no significant differences in any of these variables between the two groups. Data are expressed as mean \( (95\% \text{ CI}) \) unless otherwise stated.
has been proposed that theophylline has an effect on more peripheral airways in stable disease, we saw no difference in FVC between our treatment groups and the post-bronchodilator FVC showed smaller changes with aminophylline than with placebo.

Prior theophylline use might have confounded these effects, but this was equally distributed between the treatment limbs and the theophylline level was almost undetectable 24 hours after admission in those receiving placebo. Restriction of the analysis to the 61 patients who had not received prior treatment with theophylline did not change the spirometric outcomes. However, a different picture was seen with the early changes in arterial blood gases. Patients receiving placebo had a lower PaCO₂ and a slightly higher pH at 12 hours than those receiving placebo, a change that was more obvious in those who had not received prior treatment with theophylline. This is in keeping with the known effect of aminophylline as a ventilatory stimulant, probably due to increases in central nervous system hypoxaemia. However, these changes were clinically unimportant in our patients who were selected as having non-acidotic exacerbations. Whether this effect would benefit patients with hypercapnic respiratory failure remains to be tested, although current evidence would suggest that the use of aminophylline would best be seen as an adjunct to non-invasive ventilatory support.

The change in breathlessness (whether assessed by the Borg or visual analogue scale) and the rate of resolution of symptoms were not influenced by aminophylline treatment. Treatment was continued for approximately 30–50 hours with no sign of a clinical or physiological difference in favour of aminophylline as treatment progressed. The decision to stop treatment, which was made by clinicians unaware of the allocation, was similar in the two groups and the clinical evaluation of the success of the treatment was likewise randomly distributed. This latter helps to explain the individual clinician's belief in the value of this treatment, as it is possible to attribute benefit to treatment when improvement has been spontaneous. Similar concerns also affect the perception of side effects with withdrawal due to potential theophylline related toxicity being as common in placebo treated patients as in those who received the active drug.

The theophylline concentration achieved during active treatment was below the mid point of the therapeutic range, although in no case was it subtherapeutic. It is possible that a higher concentration might have improved lung function, but only at the risk of greater toxicity. The relatively "low" toxicity in our study may reflect our careful monitoring of theophylline use but, despite this, several patients developed nausea and the risk of uncontrolled aminophylline treatment has been well documented elsewhere.

In conclusion, our data indicate that the addition of intravenous aminophylline to nebulised bronchodilators and oral corticosteroids in the management of non-acidotic COPD patients cannot be recommended as it confers no clear benefit and potentially increases both the risk of side effects and the complexity of management.

ACKNOWLEDGEMENTS
The authors thank all patients, consultants, and staff who participated in the study. Theophylline levels were measured by the Biochemistry Department at University Hospital Aintree. Dummy theophylline levels were supplied by Deirdre Frost (research nurse).

Authors' affiliations
N Duffy, P Walker, F Diamantea, P M A Calverley, L Davies, Aintree Chest Centre and University of Liverpool Department of Medicine, University Hospital Aintree, Liverpool, UK

The study was supported by the EU CARED project (ND) and an ERS training fellowship (FD).

All authors declare no conflict of interest.

ND, PW and FD assessed the patients and collected the data, ND conducting all the final reviews. ND undertook the data analysis and wrote the manuscript together with PMAC and LD who originally developed the study protocol.

REFERENCES